FAQ on NanoViricides' NV-387 Antiviral Development Amid Measles and MPox Resurgence

What is NV-387 and what diseases is it targeting?

NV-387 is a broad-spectrum antiviral drug candidate by NanoViricides, Inc., being developed to treat Measles, MPox, broad respiratory infections, and pan-herpesvirus infections, among others.

Why is the development of NV-387 significant?

The development is significant because there are currently no approved drugs for Measles or MPox, and NV-387 aims to fill critical gaps in global antiviral preparedness amid rising case counts and vaccine failures.

How is NanoViricides advancing NV-387 for Measles treatment?

NanoViricides has begun preparations for animal efficacy studies for Measles and will make NV-387 available under FDA’s Individual Patient Expanded Access program.

What progress has been made with NV-387 for MPox treatment?

In the Democratic Republic of Congo, NanoViricides’ Phase II Clinical Trial Application for MPox has been cleared by the national ethics committee.

Who is involved in the development of NV-387?

NanoViricides, Inc., in collaboration with TheraCour Pharma, Inc., is developing NV-387, leveraging nanoviricide technology and intellectual property from TheraCour.

Where can I find more information about NanoViricides and NV-387?

For more information, visit NanoViricides’ website at www.NanoViricides.com or the latest news at https://ibn.fm/NNVC.

What are the implications of NV-387’s development for global health?

NV-387’s development could provide a much-needed treatment option for Measles and MPox, diseases with no current approved drugs, enhancing global antiviral preparedness and response.

When can we expect NV-387 to be available for patients?

NanoViricides cannot project an exact date for NV-387’s availability due to dependence on external collaborators and consultants, but it is advancing into Phase II human clinical trials.